JP2024543377A - 造血前駆体キナーゼの二官能性分解物質およびその治療的使用 - Google Patents

造血前駆体キナーゼの二官能性分解物質およびその治療的使用 Download PDF

Info

Publication number
JP2024543377A
JP2024543377A JP2024527355A JP2024527355A JP2024543377A JP 2024543377 A JP2024543377 A JP 2024543377A JP 2024527355 A JP2024527355 A JP 2024527355A JP 2024527355 A JP2024527355 A JP 2024527355A JP 2024543377 A JP2024543377 A JP 2024543377A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
inhibitors
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543377A5 (https=
Inventor
ラン ワン,
マーク エドワード ザック,
ジョン ビューエル,
フレデリック コーエン,
ライアン ペンバートン,
ハンター ピー. シュナトナ,
Original Assignee
ニューリックス セラピューティクス,インコーポレイテッド
ギリアード サイエンシーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューリックス セラピューティクス,インコーポレイテッド, ギリアード サイエンシーズ, インコーポレイテッド filed Critical ニューリックス セラピューティクス,インコーポレイテッド
Publication of JP2024543377A publication Critical patent/JP2024543377A/ja
Publication of JP2024543377A5 publication Critical patent/JP2024543377A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2024527355A 2021-11-10 2022-11-09 造血前駆体キナーゼの二官能性分解物質およびその治療的使用 Pending JP2024543377A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163263875P 2021-11-10 2021-11-10
US63/263,875 2021-11-10
PCT/US2022/049426 WO2023086399A1 (en) 2021-11-10 2022-11-09 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2024543377A true JP2024543377A (ja) 2024-11-21
JP2024543377A5 JP2024543377A5 (https=) 2025-11-07

Family

ID=85132852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527355A Pending JP2024543377A (ja) 2021-11-10 2022-11-09 造血前駆体キナーゼの二官能性分解物質およびその治療的使用

Country Status (12)

Country Link
US (2) US12091426B2 (https=)
EP (1) EP4430052A1 (https=)
JP (1) JP2024543377A (https=)
KR (1) KR20240101654A (https=)
CN (1) CN118510786A (https=)
AR (1) AR127625A1 (https=)
AU (1) AU2022388571A1 (https=)
CA (1) CA3235913A1 (https=)
IL (1) IL312361A (https=)
MX (1) MX2024005431A (https=)
TW (1) TW202334170A (https=)
WO (1) WO2023086399A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117126133A (zh) * 2023-08-14 2023-11-28 中国海洋大学 一种化合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP7472103B2 (ja) 2018-08-22 2024-04-22 クルゲン(シャンハイ),インク. トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法
WO2020092528A1 (en) * 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Hpk1の分解剤としてのヘテロ二官能性化合物
WO2021168197A1 (en) 2020-02-19 2021-08-26 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
US11739101B2 (en) * 2020-05-06 2023-08-29 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Also Published As

Publication number Publication date
KR20240101654A (ko) 2024-07-02
CN118510786A (zh) 2024-08-16
WO2023086399A1 (en) 2023-05-19
IL312361A (en) 2024-06-01
US20240018162A1 (en) 2024-01-18
MX2024005431A (es) 2024-07-19
AU2022388571A1 (en) 2024-05-09
CA3235913A1 (en) 2023-05-19
US12091426B2 (en) 2024-09-17
TW202334170A (zh) 2023-09-01
US20240400587A1 (en) 2024-12-05
AR127625A1 (es) 2024-02-14
EP4430052A1 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
US11739101B2 (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
AU2021411587B2 (en) Indazole compounds as kinase inhibitors
JP6942896B2 (ja) Parp7阻害剤としてのピリダジノン
JP7820584B2 (ja) インターロイキン-1受容体関連キナーゼの二官能性分解剤及びその治療的使用
US12091426B2 (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
SG187747A1 (en) Inhibitors of bruton's tyrosine kinase
TW202448898A (zh) 用於egfr激酶降解之化合物
TW202328129A (zh) 治療自體免疫疾病之吡唑并[3,4—b]吡啶化合物
HK40115438A (zh) 造血祖细胞激酶的双功能降解剂及其治疗用途
TWI918648B (zh) 造血前驅細胞激酶之雙官能降解劑及其治療用途
CN120957981A (zh) 基于2,4-二苯胺嘧啶的Aurora-A激酶选择性降解诱导化合物
CN115557946A (zh) 杂环内酰胺类化合物,包含其的药物组合物及其用途
HK40121612A (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
OA21863A (en) Indazole based compounds and associated methods of use.
CN117396477A (zh) 用于治疗癌症的经吡啶基取代的氧代异吲哚啉化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251029